The solution portfolio connects production execution, quality systems, laboratory data, facilities monitoring and enterprise reporting. Each area addresses a specific layer of the ISA-95 model and is scoped to produce GMP evidence that QA and operations teams can rely on during routine review and regulatory inspection.
MES and EBR
Digital batch execution reduces paper review cycles and strengthens electronic record controls for GMP production. MES captures operator actions, enforces recipe steps, manages electronic signatures and generates audit trails that reviewers can work through at a fraction of the time needed for paper batch records. A phased MES rollout starts with one high-value product family, proves review-by-exception on real batches, then expands templates, equipment integration and validation packages to the rest of the site.
Data historian and infrastructure
Industrial time-series platforms centralize validated process evidence for trending, deviation review and continuous improvement. A historian collects signals from PLCs, DCS, SCADA and equipment at high frequency, compresses them with context, and makes them available for batch correlation, environmental trending, alarm rationalization and future analytics. Tag naming, OPC UA gateways, network zones, time synchronization, retention rules and backup configuration must be governed before the historian is used to support regulated records.
ISA-95 ecosystem integration
A smart factory program is not a single-vendor replacement — it is a structured program that connects existing automation, ERP, QMS, LIMS, EMS and BMS systems through governed interfaces. The ISA-95 model defines what each layer owns and which data flows must be validated. Integration work follows an interface catalogue: each connection is classified by criticality, direction, owner, protocol and validation boundary so the overall architecture is maintainable and inspection-ready.
Integration approach and sequencing
Successful programs sequence work around compliance risk and operational pain rather than technology capability. High-value integrations — batch execution to deviation, laboratory result to release, historian to batch review — are tackled first. Low-risk reporting integrations follow after the data model is stable. Each integration slice produces an interface specification, test evidence and operating procedure before it goes live.
Quality and facilities integration
QMS, LIMS, EMS and BMS signals become stronger when connected through a governed plant data model. Deviations and CAPA are more traceable when batch records, historian evidence and environmental data are linked. LIMS results are more defensible when sample identity, instrument calibration and test conditions are recorded in context. EMS and BMS alarms are more actionable when reviewed against cleanroom standards and batch impact rules.
Typical project timeline
A brownfield smart factory program typically runs in three phases. Phase 1 (months 1–6) covers system inventory, interface cataloguing, data model definition, one high-value pilot scope and a baseline validation package. Phase 2 (months 6–18) expands validated integrations, completes MES/EBR rollout, stabilizes the historian and connects QMS/LIMS. Phase 3 (months 18–36) covers advanced analytics, AI readiness, performance management dashboards and continuous improvement routines. Each phase has a defined QA evidence package before the next phase begins.
How to use this page
Use this Pharma Smart Factory Solution Portfolio page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.
Evidence to prepare
For Pharma Smart Factory Solution Portfolio, prepare the records, owners, risks and decision criteria linked to mes and ebr, data historian and infrastructure, isa-95 ecosystem integration, integration approach and sequencing, quality and facilities integration, typical project timeline. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.
Frequently asked questions
What is the right starting point for a pharma smart factory solution program?
Start by mapping your ISA-95 layers: which systems exist at each level, who owns the data, and where regulated records are created, reviewed and retained. Then rank integration gaps by compliance risk and operational pain. The first solution scope should be one high-value workflow — batch execution, deviation review, or historian correlation — that produces measurable QA and operations outcomes before the program expands.
How long does a pharmaceutical smart factory integration program take?
A realistic brownfield program runs 24 to 36 months for full ISA-95 integration from shop floor to enterprise. The first phase covering system inventory, pilot scope and baseline validation takes 6 months. Expanding MES/EBR, historian and QMS/LIMS integrations across the site takes another 12 months. Advanced analytics, performance management and AI readiness follow in the final phase. Each phase should deliver a validated, inspection-ready evidence package before the next begins.
Do all pharma smart factory integrations require full GxP validation?
No. Validation scope follows risk. Integrations that create, modify or transfer regulated records — batch execution, electronic signatures, audit trails, laboratory results, environmental monitoring records — require formal GxP validation with documented evidence. Reporting integrations, dashboard connections and non-GxP business integrations require good engineering practice and change control, but not the same validation depth. A risk-based classification at the start of each integration scope prevents both over-validation and under-validation.